Lori Bisson serves as Chief Financial Officer of the Company. Ms. Bisson has served as our chief financial officer since January 2015. Prior to joining Soliton, Ms. Bisson worked as a financial and business development consultant as a Shareholder in Condon & Company, PC, from 2009 through December 2014, where she advised a number of life science companies. From 2005 to 2009, Ms. Bisson served as the CFO of Zeno Corporation, a medical device company focused on new technology in the aesthetics area. Ms. Bisson previously served as the CFO of Gulfstream Trading, Ltd., an international oil trading organization from 2001 to 2005. From 1995 to 2001, Ms. Bisson held various positions with Drypers Corporation, a publicly traded multinational consumer products company, where she ultimately held the title of Vice President of Integrated Solutions and oversaw accounting, information technology, and logistics for the U.S. operation. Ms. Bisson began her career at Arthur Andersen, LLP as an auditor focused on consumer products companies. Ms. Bisson also serves as an advisor to Moleculin Biotech, Inc., a drug development company traded on NASDAQ developing novel cancer therapies. Ms. Bisson earned her CPA in 1995 after earning her BBA in Accounting from Baylor University.
As the Chief Financial Officer of Soliton, the total compensation of Lori Bisson at Soliton is $858,939. There are 2 executives at Soliton getting paid more, with Christopher Capelli having the highest compensation of $1,111,190.
Lori Bisson is 48, she's been the Chief Financial Officer of Soliton since 2015. There are 4 older and 2 younger executives at Soliton. The oldest executive at Soliton, Inc. is Joe Tanner, 72, who is the Chief Operating Officer.
Lori's mailing address filed with the SEC is , C/O SOLITON, INC. 5304 ASHBROOK DRIVE, HOUSTON, TX, 77081.
Over the last 5 years, insiders at Soliton have traded over $0 worth of Soliton stock and bought 632,904 units worth $999,992 . The most active insiders traders include Walter V Klemp, Ventures Llc Remeditex a Jonathan P. Foster. On average, Soliton executives and independent directors trade stock every 126 days with the average trade being worth of $4,763,657. The most recent stock trade was executed by Ventures Llc Remeditex on 30 June 2020, trading 120,481 units of SOLY stock currently worth $999,992.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. It is developing a product for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.
Soliton executives and other stock owners filed with the SEC include: